**Signatures of copy number alterations in human cancer**. *Nature,* 2022

<https://pubmed.ncbi.nlm.nih.gov/35705804/>

**Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.** *Molecular Cancer,* 2022

<https://pubmed.ncbi.nlm.nih.gov/35689207/>

**Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma.** *Cancer Discov,* 2022

<https://pubmed.ncbi.nlm.nih.gov/34551970/>

**Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours.** *European Journal of Cancer*, 2021

<https://pubmed.ncbi.nlm.nih.gov/34933802/>

**Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders**. *Blood Adv.,*2021

<https://pubmed.ncbi.nlm.nih.gov/34424321/>

**Genomic profile of advanced breast cancer in circulating tumour DNA.** *Nat Commun.* 2021 <https://pubmed.ncbi.nlm.nih.gov/33893289/>

**Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology.** *Nat Biotechnol.* 2021 <https://pubmed.ncbi.nlm.nih.gov/33846644/>

**ddPCR-based detection of circulating tumour DNA from paediatric high grade and diffuse midline glioma patients.** Neuro-Oncology Advances, 2021 <https://doi.org/10.1093/noajnl/vdab013>

**Identification of a novel genetic locus associated with immune mediated thrombotic thrombocytopenic purpura.** *Haematologica*. 2021 <https://pubmed.ncbi.nlm.nih.gov/33596643/>

**Lineage-Independent Tumors in Bilateral Neuroblastoma.** N Engl J Med. 2020 <https://pubmed.ncbi.nlm.nih.gov/33211929/>

**Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers.**

Cancer Discov. 2020 <https://pubmed.ncbi.nlm.nih.gov/32958578/>

**Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.**

Lancet Oncol. 2020 <https://pubmed.ncbi.nlm.nih.gov/32919527/>

**Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.**

Clin Cancer Res. 2020 <https://pubmed.ncbi.nlm.nih.gov/31591187/>

[**Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favourable Outcomes.**](https://pubmed.ncbi.nlm.nih.gov/32238360/)

Cancer Discov. 2020 <https://pubmed.ncbi.nlm.nih.gov/32238360/>

**Genomic landscape of platinum resistant and sensitive testicular cancers.**

Nat Commun. 2020 <https://pubmed.ncbi.nlm.nih.gov/32366847/>

**MRI Tumour Regression Grade and Circulating Tumour DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer.**

Clin Cancer Res. 2020 <https://pubmed.ncbi.nlm.nih.gov/31852830/>

**Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.**

Nat Commun. 2020 <https://pubmed.ncbi.nlm.nih.gov/32471999/>

[**Representative Sequencing: Unbiased Sampling of Solid Tumour Tissue.**](https://pubmed.ncbi.nlm.nih.gov/32375028/)

Cell Rep. 2020 <https://pubmed.ncbi.nlm.nih.gov/32375028/>

**The KDR (VEGFR-2) Genetic Polymorphism Q472H and c-KIT Polymorphism M541L Are Associated with More Aggressive Behaviour in Astrocytic Gliomas**

Cancer Genomics & Proteomics 2020 <https://pubmed.ncbi.nlm.nih.gov/33099473/>

**Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy.**

Br J Haematol. 2020 <https://pubmed.ncbi.nlm.nih.gov/33022753/>

**Evaluation of Xpert® BCR-ABL Ultra for the confirmation of BCR-ABL1 international scale conversion factors for the molecular monitoring of chronic myeloid leukaemia.**

Int J Lab Hematol. 2020 <https://pubmed.ncbi.nlm.nih.gov/32990400/>

**A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.**

Eur J. Cancer 2019 <https://pubmed.ncbi.nlm.nih.gov/31543384/>